Abatacept: A novel treatment for rheumatoid arthritis

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 14, 2007, Pages 2371-2379

  Lundquist, Lisa M ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

Abatacept; Biologic; Co stimulation; CTLA 4Ig; Inadequate response; Rheumatoid arthritis; T cells; Tumor necrosis factor

Indexed keywords

ABATACEPT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PNEUMOCOCCUS VACCINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TETANUS TOXOID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DOSE RESPONSE; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; HUMAN; INFECTION; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NEOPLASM; PHARMACODYNAMICS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; STREPTOCOCCUS INFECTION; T LYMPHOCYTE ACTIVATION; TETANUS; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUGS, INVESTIGATIONAL; HUMANS; IMMUNOCONJUGATES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35548990621     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.14.2371     Document Type: Article

References (25)

1. SMOLEN JS, STEINER G: Therapeutic strategies for rheumatoid arthritis. Nat. Rev. Drug Discov. (2003) 2(6):473-488.
2. KREMER JM: Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann. Intern. Med. (2001) 134(8):695-706.
3. DUREZ P, VAN DEN BOSCH F, CORLUY L et al.: A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology (Oxford) (2005) 44(4):465-468.
4. HARAOUI B, CAMERON L, OUELLET M, WHITE B: Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J. Rheumatol. (2006) 33(1):31-36.
5. KEYSTONE EC, KAVANAUGH AF, SHARP JT et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-TNF monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. (2004) 50(5):1400-1411.
6. MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. (1999) 130(6):478-486.
7. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-TNF α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. (2003) 48(1):35-45.
8. FLENDRIE M, VISSERS WH, CREEMERS MC et al.: Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res. Ther. (2005) 7(3):R666-R676.
9. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT study group. Lancet(1999) 354(9194):1932-1939.
10. BRESNIHAN B: Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis. Ann. Rheum. Dis. (2002) 61(Suppl. 2):ii74-77.
11. COHEN S, HURD E, CUSH J et al.: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46(3):614-624.
12. YAMADA A, SALAMA AD, SAYEGH MH: The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J. Am. Soc. Nephrol. (2002) 13(2):559-575.
13. CHOY EH, PANAYI GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. (2001) 344(12):907-916.
14. MORELAND LW, ALTEN R, VAN DEN BOSCH F et al.: Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. (2002) 46(6):1470-1479.
15. WEISMAN M, DUREZ P, HALLEGUA D et al.: Reduction of inflammatory biomarker response by abatacept in the treatment of rheumatoid arthritis. J. Rheumatol. (2006).
16. KREMER JM, GENANT HK, MORELAND LW et al.: Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. (2006) 144(12):865-876.
17. KREMER JM, DOUGADOS M, EMERY P et al.: Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a Phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. (2005) 52(8):2263-2271.
18. KREMER JM, WESTHOVENS R, LEON M et al.: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. (2003) 349(20):1907-1915.
19. GENOVESE MC, BECKER JC, SCHIFF M et al.: Abatacept for rheumatoid arthritis refractory to TNF α inhibition. N. Engl. J. Med. (2005) 353(11):1114-1123.
20. FELSON DT, ANDERSON JJ, BOERS M et al.: The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The committee on outcome measures in rheumatoid arthritis clinical trials. Arthritis Rheum. (1993) 36(6):729-740.
21. FRANSEN J, VAN RIEL P et al.: The disease activity score and the EULAR response criteria. Clin. Exp. Rheum. (2005) 23(5):S93-99.
22. WEINBLATT M, COMBE B, COVUCCI A et al.: Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs. Arthritis Rheum. (2006) 54(9):2807-2816.
23. WEINBLATT M, SCHIFF M, GOLDMAN A et al.: Selective costimularion modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann. Rheum. Dis. (2007) 66(2):228-234.
24. TAY L, LEON F, VRATSANOS G, RAYMOND R, CORBO M: Vaccination response to tetanus and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res. Ther. (2007) 9(2):R38.
25. FURST DE, BREEDVELD FC, KALDEN JR et al.: Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann. Rheum. Dis. (2006) 65(Suppl. 3):iii2-15.